Prof. R. StephanieHuang – Oncology and Precision Medicine – Best Researcher Award 

Published on by Oncology

Prof. R. StephanieHuang - Oncology and Precision Medicine - Best Researcher Award 

University Of Minnesota - Minneapolis, MN - United States

Author Profile

Scopus 

Orcid

Early Academic Pursuits

Dr. Rong Stephanie Huang's academic journey began with her pursuit of pharmacology at the University of Minnesota, where she eventually earned the title of Distinguished McKnight University Professor. Her early academic pursuits laid the foundation for her distinguished career in the field.

Professional Endeavors

Throughout her career, Dr. Huang has held prestigious academic appointments, including her current position in the Department of Experimental and Clinical Pharmacology at the University of Minnesota. Her commitment to advancing pharmacology is evident in her leadership roles and contributions to various professional societies.

Contributions and Research Focus on Oncology and Precision Medicine

Dr. Huang's research primarily focuses on personalized and precision medicine, particularly in oncology. Her work aims to tailor treatments to individual patients by understanding the genetic and molecular mechanisms underlying cancer progression. This research has significant implications for improving patient outcomes in cancer treatment.

Impact and Influence

As a respected leader in pharmacology, Dr. Huang's influence extends beyond her research. Her leadership roles in organizations such as the International Pharmaceutical Federation (FIP) highlight her dedication to advancing the field on a global scale. Her contributions have shaped the landscape of personalized medicine and oncology research.

Academic Citations

Dr. Huang's research has garnered substantial attention within the academic community, evidenced by the numerous citations her work has received. Her findings have contributed to advancing knowledge in pharmacology, particularly in the realm of personalized medicine and cancer research.

Legacy and Future Contributions

Dr. Huang's legacy is characterized by her significant contributions to pharmacology and personalized medicine. Her ongoing leadership roles and mentorship efforts ensure that her impact will endure for future generations of pharmacologists. As she continues her research and advocacy, Dr. Huang will undoubtedly leave a lasting legacy in the field.

Notable Publications

Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis.

Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma.

Integration of pan-cancer cell line and single-cell transcriptomic profiles enables inference of therapeutic vulnerabilities in heterogeneous tumors.

A review of computational methods for predicting cancer drug response at the single-cell level through integration with bulk RNAseq data.

 

 

 

Dr. Durre Nayab – Cancer Research – Best Researcher Award

Published on by Oncology

Dr. Durre Nayab - Cancer Research - Best Researcher Award

Technische Universitat Dresden - Germany 

AUTHOR PROFILE

Google Scholar

EARLY ACADEMIC PURSUITS:

Durr-e-Nayab's academic journey began with a Bachelor's degree in Computer Systems Engineering from the University of Engineering and Technology, Peshawar, Pakistan, followed by a Master's in Computer Systems Engineering from the same institution. Later, she achieved a Ph.D. in Electrical Engineering from the University of Engineering and Technology, Peshawar, with a research focus on Adaptive Expanding Ring Search Based Per Hop Routing Rendition in Mobile Ad Hoc Networks (MANETs) using Machine Learning.

PROFESSIONAL ENDEAVORS:

Nayab has accumulated 11 years of teaching experience and 6 years of research experience. She has held various positions, including Lecturer & Batch Advisor at the University of Engineering and Technology, Peshawar, and Research Assistant at the Center for Intelligent Systems and Networks Research. Additionally, she has served as a Lecturer in Computer Science at City University of Science and Technology and Institute of Business and Management Sciences.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER RESEARCH

Her contributions extend to research projects, including a significant role as a Research Assistant in R & D Funded Projects at the Center for Intelligent Systems and Networks Research. Notable projects involve secure and intelligent transportation systems, secure billing frameworks, traffic pattern analysis, and autonomous situation-based alerts using wireless sensor networks.

IMPACT AND INFLUENCE:

Dr. Nayab's impact is evident through her contributions to projects funded by ICT R & D, Ministry of IT Pakistan, addressing critical issues such as congestion control, electricity theft, and traffic patterns in Pakistan. Her role as a Co-PI at the National Center for Artificial Intelligence showcases her influence in shaping intelligent systems design in Pakistan.

ACADEMIC CITES:

Dr. Nayab's research has made a substantial impact, with publications in reputable journals, including "Applied Computational Intelligence and Soft Computing," "Annals of Telecommunication," and "Computers, Materials & Continua."

LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Nayab's legacy is marked by her dedication to research and education, particularly in the fields of Mobile Ad Hoc Networks, Machine Learning, and Artificial Intelligence. Her future contributions are anticipated in her role as a Post-Doctoral Researcher at TU Dresden, focusing on Transport Modeling, Cancer Research and Simulation.

NOTABLE PUBLICATIONS

Performance Augmentation of Base Classifiers Using Adaptive Boosting Framework for Medical Datasets. 2023

Effects of dataset attacks on machine learning models in E-health. 2023

SP-DSTS-MIMO Scheme aided H.266 for reliable high data-rate mobile video-communication. 2023

Data Augmentation and Random Multi-Model Deep Learning for Data Classification. 2022

Sparse Crowd Flow Analysis of Tawaaf of Kaaba during the COVID-19 Pandemic. 2022

 

Cancer Drugs and Vaccines

Published on by Oncology

Cancer Drugs and Vaccines

Introduction: Cancer Drugs and Vaccines are at the forefront of oncology research and treatment, offering promising solutions in the fight against cancer. These innovative therapies aim to improve patient outcomes, enhance survival rates, and provide hope for individuals battling this devastating disease.

Subtopics in Cancer Drugs and Vaccines:

Immunotherapy in Cancer Treatment: Immunotherapy harnesses the power of the immune system to target and destroy cancer cells. Explore the latest developments in checkpoint inhibitors, CAR-T cell therapy, and immune checkpoint blockade.

Targeted Therapies: Targeted cancer drugs are designed to specifically target cancer cells with minimal damage to healthy tissues. Delve into the mechanisms and effectiveness of these precision therapies.

Vaccine-Based Approaches: Investigate the role of cancer vaccines in preventing or treating various types of cancer. Discover the development and clinical trials of vaccines that stimulate the immune system to recognize and combat cancer cells.

Combination Therapies: Combinatorial approaches involving a mix of drugs, vaccines, and other treatments are gaining traction. Explore how these synergistic combinations are revolutionizing cancer care.

Personalized Medicine: Learn about the concept of tailoring cancer treatments to individual patients based on their genetic and molecular profiles. Explore the advancements in genomic medicine and its impact on cancer drug development.

Resistance Mechanisms: Understand the challenges posed by drug resistance in cancer treatment and how researchers are addressing these issues through innovative strategies.

Emerging Biomarkers: Discover the latest biomarkers used in cancer diagnosis, prognosis, and treatment selection, paving the way for more personalized and effective therapies.

Clinical Trials and Regulatory Challenges: Examine the critical role of clinical trials in evaluating the safety and efficacy of cancer drugs and vaccines, along with the regulatory processes that govern their approval.

Future Trends in Cancer Therapeutics: Explore the cutting-edge technologies and trends shaping the future of cancer treatment, from nanomedicine to gene editing and beyond.

Patient Perspectives and Support: Consider the holistic approach to cancer care, including patient support systems, psychosocial aspects, and quality of life improvements alongside drug and vaccine development.